Outcome of Pregnancy in the Era of PEGylated Interferon-α2a in Females with Chronic Myeloid Leukemia: An Experience from Qatar
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative neoplasm characterized by increased proliferation of the granulocytic cell line without loss of its capacity to differentiate. It accounts for 20% of all adults affected by leukemia. Tyrosine kinase inhibitors revolutionized the treatment for CML and improved quality of life. Fertility is an important issue for both males and females. Here, we report our experience with a pregnant female with CML, and shed light on safety and efficacy of PEGylated interferon-αa in pregnant women with CML and its outcome.
Other Information
Published in: Case Reports in Oncology
License: https://creativecommons.org/licenses/by-nc/4.0/
See article on publisher's website: https://dx.doi.org/10.1159/000506590
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
KargerPublication Year
- 2020
License statement
This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International LicenseInstitution affiliated with
- Hamad Medical Corporation
- National Center for Cancer Care and Research - HMC